Processa Pharmaceuticals (PCSA) Total Liabilities (2012 - 2026)
Processa Pharmaceuticals' (PCSA) quarterly Total Liabilities came in at $2.0 million in Q1 2026, up 54.34% YoY from $1.3 million in Q1 2025, and down 11.45% on a QoQ basis from $2.2 million in Q4 2025.
Processa Pharmaceuticals (PCSA) Total Liabilities (2012 - 2026) Analysis & Trends
Processa Pharmaceuticals (PCSA) has 15 years of Total Liabilities data on file, last reported at $2.0 million in Q1 2026.
- Quarterly Total Liabilities rose 54.34% year-over-year to $2.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $2.0 million (up 54.34% YoY) and the FY2025 annual result came in at $2.2 million, up 45.86% from the prior year.
- Total Liabilities fell to $2.0 million in Q1 2026, from $2.2 million in the prior quarter.
- In the past five years, Total Liabilities ranged from a high of $2.3 million in Q1 2023 to a low of $797484.0 in Q4 2023.
- A 5-year average of $1.5 million and a median of $1.4 million in 2022 frame the typical range for Total Liabilities.
- Annual changes were most pronounced in 2023 — Total Liabilities jumped 115.26% — and 2024, when it plunged 53.66%.
- Tracing PCSA's Total Liabilities over 5 years: stood at $1.1 million in 2022, then tumbled by 30.6% to $797484.0 in 2023, then jumped by 92.24% to $1.5 million in 2024, then jumped by 45.86% to $2.2 million in 2025, then decreased by 11.45% to $2.0 million in 2026.
- The last three Total Liabilities figures came in at $2.0 million (Q1 2026), $2.2 million (Q4 2025), and $1.8 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.83 Bn | 130.98 Bn | 2.84 Bn | 7.18 Bn |
| 2 | Regeneron Pharmaceuticals | 85.79 Bn | 77.79 Bn | 3.93 Bn | 10.02 Bn |
| 3 | Argenx Se | 64.95 Bn | 59.77 Bn | 1.37 Bn | 1.62 Bn |
| 4 | Moderna | 58.59 Bn | 53.46 Bn | 52.00 Mn | 4.20 Bn |
| 5 | BeOne Medicines | 41.93 Bn | 36.83 Bn | 1.53 Bn | 4.00 Bn |
| 6 | Alnylam Pharmaceuticals | 31.52 Bn | 28.21 Bn | 992.69 Mn | 4.20 Bn |
| 7 | BioNTech SE | 27.98 Bn | 9.58 Bn | 668.28 Mn | 3.22 Bn |
| 8 | Insmed | 27.42 Bn | 26.26 Bn | 358.27 Mn | 1.35 Bn |
| 9 | Royalty Pharma | 27.33 Bn | 26.49 Bn | - | 10.03 Bn |
| 10 | Processa Pharmaceuticals | 5.75 Mn | 5.75 Mn | - | 2.39 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.98 Mn |
| Dec 31, 2025 | 2.24 Mn |
| Sep 30, 2025 | 1.75 Mn |
| Jun 30, 2025 | 2.07 Mn |
| Mar 31, 2025 | 1.28 Mn |
| Dec 31, 2024 | 1.53 Mn |
| Sep 30, 2024 | 1.22 Mn |
| Jun 30, 2024 | 1.58 Mn |
| Mar 31, 2024 | 1.06 Mn |
| Dec 31, 2023 | 797,484.00 |
| Sep 30, 2023 | 914,847.00 |
| Jun 30, 2023 | 930,741.00 |
| Mar 31, 2023 | 2.29 Mn |
| Dec 31, 2022 | 1.15 Mn |
| Sep 30, 2022 | 1.36 Mn |
| Jun 30, 2022 | 1.58 Mn |
| Mar 31, 2022 | 1.06 Mn |
| Dec 31, 2021 | 978,405.00 |
| Sep 30, 2021 | 1.82 Mn |
| Jun 30, 2021 | 1.90 Mn |